Résumé
Background: Polysensitivity is defined as three or more positive patch test reactions. The role of filaggrin gene (FLG) loss-of-function mutations in patients with polysensitivity has not been studied when barrier bypass and possible preceding barrier damage have been excluded. Objectives: To determine whether FLG loss of function mutations play a role in patients with multiple contact sensitivities when barrier bypass is excluded. Methods: One hundred and sixty-nine patients with three or more, non-cross-reacting, positive patch test reactions were prospectively enrolled in this study. Exclusion criteria were a history of hand dermatitis, nickel and metal implants, and stasis dermatitis. Subjects were patch tested with the North American extended patch test series, and with other relevant haptens. DNA was obtained and sequenced for the following FLG loss-of-function mutations: R501X, 2282del4, R2447X, and S3247X. Results: One hundred and sixty-five patients were genotyped for the four FLG mutations. There was a significant association between R501X mutation and polysensitivity. For the other three tested mutations, there were no significant associations with polysensitivity. When all mutations were combined, there was a significant association between loss-of-function FLG mutations and polysensitivity in patients with a history of atopic dermatitis. Conclusion: When skin barrier bypass is excluded, there is a significant association between polysensitivity and FLG loss-of-function mutations.
Langue d'origine | English |
---|---|
Pages (de-à) | 354-358 |
Nombre de pages | 5 |
Journal | Contact Dermatitis |
Volume | 80 |
Numéro de publication | 6 |
DOI | |
Statut de publication | Published - juin 2019 |
Note bibliographique
Funding Information:This study was supported by funding from the Canadian Dermatology Foundation and from an investigator-initiated grant (SG141) from Astellas Pharma Canada Inc. Filaggrin research in the McLean laboratory is supported by grants from the British Skin Foundation, the National Eczema Society, the Medical Research Council (ref. G0700314), and the Welcome Trust (ref. 090066/B/09/Z and 092530/Z/10/Z), and donations from anonymous families affected by eczema in the Tayside Region of Scotland; Astellas Pharma Canada Inc., Grant/Award Number: Investigator-initiated grant (SG141); Canadian Dermatology Foundation; Medical Research Council UK, Grant/Award Number: G0700314; Wellcome Trust, Grant/Award Numbers: 090066/B/09/Z, 092530/Z/10/Z
Publisher Copyright:
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
ASJC Scopus Subject Areas
- Immunology and Allergy
- Dermatology
PubMed: MeSH publication types
- Journal Article